[go: up one dir, main page]

MX2018005462A - Composiciones inmunogénicas de rsv quimérico y métodos de uso. - Google Patents

Composiciones inmunogénicas de rsv quimérico y métodos de uso.

Info

Publication number
MX2018005462A
MX2018005462A MX2018005462A MX2018005462A MX2018005462A MX 2018005462 A MX2018005462 A MX 2018005462A MX 2018005462 A MX2018005462 A MX 2018005462A MX 2018005462 A MX2018005462 A MX 2018005462A MX 2018005462 A MX2018005462 A MX 2018005462A
Authority
MX
Mexico
Prior art keywords
methods
immunogenic compositions
chimeric rsv
rsv
respiratory syncytial
Prior art date
Application number
MX2018005462A
Other languages
English (en)
Inventor
l moore Martin
ROSTAD Christina
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Publication of MX2018005462A publication Critical patent/MX2018005462A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18521—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C12N2760/18562—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción se refiere a una vacuna viva atenuada de virus sincitial respiratorio (RSV) quimérico y composiciones inmunogénicas, y métodos de uso. En determinadas modalidades, el virus sincitial respiratorio quimérico tiene un patrón génico mutado que codifica una proteína F de RSV con M en la posición 79, R en la posición 191, K en la posición 357 y/o Y en la posición 371.
MX2018005462A 2015-10-29 2016-10-27 Composiciones inmunogénicas de rsv quimérico y métodos de uso. MX2018005462A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562247962P 2015-10-29 2015-10-29
US201662334547P 2016-05-11 2016-05-11
PCT/US2016/058976 WO2017075125A1 (en) 2015-10-29 2016-10-27 Chimeric RSV, Immunogenic Compositions, and Methods of Use

Publications (1)

Publication Number Publication Date
MX2018005462A true MX2018005462A (es) 2018-08-01

Family

ID=58630734

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005462A MX2018005462A (es) 2015-10-29 2016-10-27 Composiciones inmunogénicas de rsv quimérico y métodos de uso.

Country Status (10)

Country Link
US (2) US11235050B2 (es)
EP (1) EP3368547A4 (es)
JP (2) JP7311872B2 (es)
KR (1) KR20180085730A (es)
CN (1) CN108602858A (es)
BR (1) BR112018008708A2 (es)
CA (1) CA3003726A1 (es)
MX (1) MX2018005462A (es)
SG (1) SG11201803581VA (es)
WO (1) WO2017075125A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2970981T3 (pl) 2013-03-14 2021-07-05 Emory University Rekombinowany RSV z cichymi mutacjami, szczepionki i związane z nimi sposoby
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
MA52910A (fr) 2016-04-05 2021-04-21 Janssen Vaccines & Prevention Bv Protéine f de pré-fusion du vrs soluble et stabilisée pour son utilisation dans la prophylaxie d'un infection vrs
EP3606942B1 (en) 2017-04-04 2025-06-11 University of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
KR20250067954A (ko) 2018-02-28 2025-05-15 유니버시티 오브 워싱톤 자기 조립 나노구조 백신
EP3880243A1 (en) * 2018-11-13 2021-09-22 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
KR20240004448A (ko) * 2021-04-08 2024-01-11 코다제닉스 인코포레이티드 호흡기 세포융합 바이러스에 대한 면역 반응을 유도하는 방법
US12304929B2 (en) * 2021-04-12 2025-05-20 Sk Bioscience Co., Ltd. Recombinant RSV live vaccine strain and the preparing method thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
IL105456A (en) 1992-04-21 1996-12-05 American Home Prod Vaccines of attenuated respiratory syncytial virus
AT401526B (de) 1993-02-10 1996-09-25 Scheirer Winfried Reagenzlösung zur stabilisierung der lumineszenz bei der luciferasemessung
DE69532369T3 (de) 1994-07-18 2010-11-04 Conzelmann, Karl-Klaus, Prof. Dr. Rekombinantes infektiöses nicht-in-Segmente-geteiltes, negativ-Strange-RNS-Virus
US7465574B2 (en) 1994-09-30 2008-12-16 Medimmune, Llc Recombinant RSV virus expression systems and vaccines
JPH11512609A (ja) 1995-09-27 1999-11-02 アメリカ合衆国 クローン化されたヌクレオチド配列からの感染性ＲＳウイルス（ｒｅｓｐｉｒａｔｏｒｙ ｓｙｎｃｙｔｉａｌ ｖｉｒｕｓ）の生産
US6923971B2 (en) 1995-09-27 2005-08-02 The United States Of America As Represented By The Department Of Health & Human Services Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes
US6689367B1 (en) 1995-09-27 2004-02-10 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
US7485440B2 (en) 1995-09-27 2009-02-03 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US6713066B1 (en) 1996-07-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US7846455B2 (en) 1996-07-15 2010-12-07 The United States Of America As Represented By The Department Of Health And Human Services Attenuated chimeric respiratory syncytial virus
US6214805B1 (en) 1996-02-15 2001-04-10 The United States Of America As Represented By The Department Of Health And Human Services RNase L activators and antisense oligonucleotides effective to treat RSV infections
BRPI9710363B8 (pt) 1996-07-15 2021-07-06 Us Gov Health & Human Serv partìcula de vìrus sincicial respirátorio recombinante (rsv) infeccioso atenuado, vacina para induzir proteção contra o vìrus sincicial respiratório recombinante (rsv), vetor de expressão, e, método de produção de um vìrus sincicial respiratório recombinante (rsv) infeccioso.
US6699476B1 (en) 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
US6074859A (en) 1997-07-08 2000-06-13 Kikkoman Corporation Mutant-type bioluminescent protein, and process for producing the mutant-type bioluminescent protein
US20040005542A1 (en) 2001-06-22 2004-01-08 Krempl Christine D Respiratory syncytial virus vaccines expressing protective antigens from promotor- proximal genes
US20020018780A1 (en) * 2000-05-25 2002-02-14 Scott Koenig Epitope-based vaccine for respiratory syncytial virus F-protein
ATE469170T1 (de) 2003-03-28 2010-06-15 Medimmune Llc Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320
WO2005061698A1 (en) 2003-12-24 2005-07-07 De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Volksgezondheid, Welzijn En Sport A respiratory syncytial virus with a genomic deficiency complemented in trans
CA2587084C (en) 2004-10-08 2019-07-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Modulation of replicative fitness by using less frequently used synonym ous codons
US7951384B2 (en) 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
EP2099486A2 (en) 2006-11-30 2009-09-16 Government Of The United States Of America, As Represented by the Secretary Codon modified immunogenic compositions and methods of use
MX349825B (es) 2007-03-30 2017-08-15 Univ New York State Res Found Virus atenuados utiles para vacunas.
WO2010039224A2 (en) 2008-09-30 2010-04-08 University Of Massachusetts Medical School Respiratory syncytial virus (rsv) sequences for protein expression and vaccines
EP2346990B1 (en) 2008-11-05 2016-01-06 Merck Sharp & Dohme Corp. Live, attentuated respiratory syncytial virus
EP2370099B1 (en) 2008-12-09 2016-04-20 Novavax, Inc. Modified rsv f proteins and methods of their use
EP3178490B1 (en) 2009-07-15 2022-04-20 GlaxoSmithKline Biologicals S.A. Rsv f protein compositions and methods for making same
WO2011046925A1 (en) 2009-10-12 2011-04-21 Technovax, Inc. Respiratory syncytial virus (rsv) virus-like particles (vlps)
US10227569B2 (en) 2011-04-12 2019-03-12 Emory University Respiratory syncytial virus expression vectors
SI3275892T1 (sl) 2011-05-13 2020-06-30 Glaxosmithkline Biologicals S.A. Prefuzijski RSV F antigeni
JP2014520805A (ja) 2011-07-06 2014-08-25 ナノバイオ コーポレーション ヒト呼吸器合胞体ウイルスワクチン
US8816081B2 (en) 2012-08-06 2014-08-26 Basf Se Boron containing perylene monoimides, a process for their production, their use as building blocks for the production of perylene monoimide derivatives, monoimide derivatives and their use in dye-sensitized solar cells
PL2954049T3 (pl) 2013-02-08 2023-10-16 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Atenuacja ludzkiego syncytialnego wirusa oddechowego przez deoptymalizację par kodonów w skali genomu
HRP20240996T1 (hr) 2013-03-13 2024-10-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefuzija rsv f proteina i njihova uporaba
US9738689B2 (en) * 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
US9060975B2 (en) * 2013-03-14 2015-06-23 Mucosis Bv Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
PL2970981T3 (pl) 2013-03-14 2021-07-05 Emory University Rekombinowany RSV z cichymi mutacjami, szczepionki i związane z nimi sposoby

Also Published As

Publication number Publication date
US12257296B2 (en) 2025-03-25
JP7311872B2 (ja) 2023-07-20
CA3003726A1 (en) 2017-05-04
CN108602858A (zh) 2018-09-28
JP2023100654A (ja) 2023-07-19
SG11201803581VA (en) 2018-05-30
WO2017075125A1 (en) 2017-05-04
US20230293660A1 (en) 2023-09-21
EP3368547A1 (en) 2018-09-05
JP2019500320A (ja) 2019-01-10
EP3368547A4 (en) 2019-06-05
US20180333477A1 (en) 2018-11-22
US11235050B2 (en) 2022-02-01
KR20180085730A (ko) 2018-07-27
BR112018008708A2 (en) 2018-11-06

Similar Documents

Publication Publication Date Title
MX2018005462A (es) Composiciones inmunogénicas de rsv quimérico y métodos de uso.
PH12018500856A1 (en) Respiratory syncytial virus vaccine
ZA202403393B (en) Synthetic chimeric poxviruses
WO2016019134A8 (en) Flagellin-based agents and uses including effective vaccination
WO2017070626A3 (en) Respiratory virus vaccines
MY192848A (en) Compositions and methods for the treatment of hemoglobinopathies
PH12016501441B1 (en) Chimeric alkaline phosphatase-like proteins
EP4501318A3 (en) Nucleic acid vaccines
MX2016016722A (es) Coronavirus.
MY169352A (en) Vaccine against rsv
MX2020011586A (es) Virus vaccinia quimerico sintetico.
SG10201601501QA (en) Preparation of 2,2`-biaryls in the presence of molybdenum(v) chloride
MX2017000394A (es) Vacunas para virus influenza y usos de las mismas.
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
SG11202003800YA (en) Zika vaccines and immunogenic compositions, and methods of using the same
MX387421B (es) Producción de virus en huevos aviares.
ZA201701000B (en) Attenuated bovine coronavirus and related vaccines
MY191539A (en) Streptococcal vaccine
SG10201808278TA (en) Polishing composition and polishing method
PH12016502002A1 (en) Novel bacteriophage and composition comprising same
SG11202004863QA (en) Zika vaccines and immunogenic compositions, and methods of using the same
EP3939604A3 (en) Influenza hemagglutinin protein vaccines
MX2017008390A (es) Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato.
SG10202012175YA (en) Modified rna encoding vegf-a polypeptides, formulations, and uses relating thereto
ZA201800940B (en) Use of il-3, il-33, and il-12p40 for characterization of the respiratory infections by syncytial respiratory virus